1145671-52-8 Usage
Description
6,7-bis(2-methoxyethoxy)-N-phenylquinazolin-4-amine is a chemical compound with a complex structure, characterized by its quinazoline core and phenyl group attached to the nitrogen atom. It is a derivative of quinazoline, a heterocyclic compound with potential applications in various fields due to its unique chemical properties.
Uses
Used in Pharmaceutical Industry:
6,7-bis(2-methoxyethoxy)-N-phenylquinazolin-4-amine is used as an active pharmaceutical ingredient (API) for the development of novel therapeutic agents. Its unique chemical structure allows it to interact with specific biological targets, making it a promising candidate for the treatment of various diseases.
Used in Anticancer Applications:
In the field of oncology, 6,7-bis(2-methoxyethoxy)-N-phenylquinazolin-4-amine is used as an antineoplastic agent, specifically targeting cancer cells by inhibiting the growth and proliferation of tumor cells. Its mechanism of action may involve the modulation of various signaling pathways involved in cancer cell survival and growth.
Used in Drug Synthesis:
6,7-bis(2-methoxyethoxy)-N-phenylquinazolin-4-amine is also used as a key intermediate in the synthesis of other pharmaceutical compounds, particularly those with potential applications in the treatment of cancer and other diseases. Its versatile chemical structure allows for further functionalization and modification to develop new drugs with improved efficacy and selectivity.
Used in Research and Development:
6,7-bis(2-methoxyethoxy)-N-phenylquinazolin-4-amine is utilized in research laboratories for the study of its biological activities and potential applications in drug discovery. It serves as a valuable tool for understanding the underlying mechanisms of various diseases and for the development of new therapeutic strategies.
It is important to note that the specific applications and uses of 6,7-bis(2-methoxyethoxy)-N-phenylquinazolin-4-amine may vary depending on the context and the ongoing research in the field. Further studies and clinical trials are necessary to fully understand its potential and to optimize its use in various applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1145671-52-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,4,5,6,7 and 1 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1145671-52:
(9*1)+(8*1)+(7*4)+(6*5)+(5*6)+(4*7)+(3*1)+(2*5)+(1*2)=148
148 % 10 = 8
So 1145671-52-8 is a valid CAS Registry Number.
1145671-52-8Relevant articles and documents
Discovery of quinazoline derivatives as a novel class of potent and in vivo efficacious LSD1 inhibitors by drug repurposing
Li, Zhonghua,Li, Zhongrui,Ma, Jinlian,Miao, Jinxin,Qin, Tingting,Yang, Nian,Zhang, Xinhui,Zhang, Zhenqiang,Zhao, Taoqian,Zhao, Xuan
, (2021/08/19)
Histone lysine-specific demethylase 1 (LSD1) is an important epigenetic modulator, and is implicated in malignant transformation and tumor pathogenesis in different ways. Therefore, the inhibition of LSD1 provides an attractive therapeutic target for cancer therapy. Based on drug repurposing strategy, we screened our in-house chemical library toward LSD1, and found that the EGFR inhibitor erlotinib, an FDA-approved drug for lung cancer, possessed low potency against LSD1 (IC50 = 35.80 μM). Herein, we report our further medicinal chemistry effort to obtain a highly water-soluble erlotinib analog 5k (>100 mg/mL) with significantly enhanced inhibitory activity against LSD1 (IC50 = 0.69 μM) as well as higher specificity. In MGC-803 cells, 5k suppressed the demethylation of LSD1, indicating its cellular activity against the enzyme. In addition, 5k had a remarkable capacity to inhibit colony formation, suppress migration and induce apoptosis of MGC803 cells. Furthermore, in MGC-803 xenograft mouse model, 5k treatment resulted in significant reduction in tumor size by 81.6% and 96.1% at dosages of 40 and 80 mg/kg/d, respectively. Our findings indicate that erlotinib-based analogs provide a novel structural set of LSD1 inhibitors with potential for further investigation, and may serve as novel candidates for the treatment of LSD1-overexpressing cancers.
